Trial Profile
Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms VASCUVALDIC 2
- 24 Mar 2017 New trial record
- 10 Mar 2017 Status changed from recruiting to completed, according to results published in the Gastroenterology.
- 10 Mar 2017 Results published in the Gastroenterology